These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 17416424

  • 1. PPAR-gamma: therapeutic target for ischemic stroke.
    Culman J, Zhao Y, Gohlke P, Herdegen T.
    Trends Pharmacol Sci; 2007 May; 28(5):244-9. PubMed ID: 17416424
    [Abstract] [Full Text] [Related]

  • 2. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.
    Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J.
    Eur J Neurosci; 2005 Jul; 22(1):278-82. PubMed ID: 16029218
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 4. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J.
    J Neurochem; 2006 Apr; 97(2):435-48. PubMed ID: 16539667
    [Abstract] [Full Text] [Related]

  • 5. Neuroprotective effects of prostaglandin A(1) in rat models of permanent focal cerebral ischemia are associated with nuclear factor-kappaB inhibition and peroxisome proliferator-activated receptor-gamma up-regulation.
    Zhang HL, Gu ZL, Savitz SI, Han F, Fukunaga K, Qin ZH.
    J Neurosci Res; 2008 Apr; 86(5):1132-41. PubMed ID: 18074385
    [Abstract] [Full Text] [Related]

  • 6. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.
    Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M.
    Biochem Soc Trans; 2006 Dec; 34(Pt 6):1341-6. PubMed ID: 17073815
    [Abstract] [Full Text] [Related]

  • 7. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB.
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [Abstract] [Full Text] [Related]

  • 8. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
    Zieleniak A, Wójcik M, Woźniak LA.
    Arch Immunol Ther Exp (Warsz); 2008 May; 56(5):331-45. PubMed ID: 18836859
    [Abstract] [Full Text] [Related]

  • 9. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms.
    Thal SC, Heinemann M, Luh C, Pieter D, Werner C, Engelhard K.
    J Neurotrauma; 2011 Jun; 28(6):983-93. PubMed ID: 21501066
    [Abstract] [Full Text] [Related]

  • 10. Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat.
    Allahtavakoli M, Moloudi R, Arababadi MK, Shamsizadeh A, Javanmardi K.
    Brain Res; 2009 May 19; 1271():121-7. PubMed ID: 19332033
    [Abstract] [Full Text] [Related]

  • 11. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ, Usher MG, Mortensen RM.
    Circ Res; 2008 Feb 15; 102(3):283-94. PubMed ID: 18276926
    [Abstract] [Full Text] [Related]

  • 12. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.
    Guo L, Tabrizchi R.
    Pharmacol Ther; 2006 Jul 15; 111(1):145-73. PubMed ID: 16305809
    [Abstract] [Full Text] [Related]

  • 13. Peroxisome proliferator-activated receptors and acute lung injury.
    Cuzzocrea S.
    Curr Opin Pharmacol; 2006 Jun 15; 6(3):263-70. PubMed ID: 16580256
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
    Patzer A, Zhao Y, Stöck I, Gohlke P, Herdegen T, Culman J.
    Eur J Neurosci; 2008 Nov 15; 28(9):1786-94. PubMed ID: 18973594
    [Abstract] [Full Text] [Related]

  • 15. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B, Fonseca V.
    Vascul Pharmacol; 2006 Jul 15; 45(1):29-35. PubMed ID: 16777491
    [Abstract] [Full Text] [Related]

  • 16. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock.
    Abdelrahman M, Sivarajah A, Thiemermann C.
    Cardiovasc Res; 2005 Mar 01; 65(4):772-81. PubMed ID: 15721857
    [Abstract] [Full Text] [Related]

  • 17. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
    Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E.
    Neuroscience; 2011 Oct 27; 194():250-61. PubMed ID: 21839812
    [Abstract] [Full Text] [Related]

  • 18. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.
    Collino M, Patel NS, Thiemermann C.
    Ther Adv Cardiovasc Dis; 2008 Jun 27; 2(3):179-97. PubMed ID: 19124421
    [Abstract] [Full Text] [Related]

  • 19. Altered PPARgamma expression and activation after transient focal ischemia in rats.
    Victor NA, Wanderi EW, Gamboa J, Zhao X, Aronowski J, Deininger K, Lust WD, Landreth GE, Sundararajan S.
    Eur J Neurosci; 2006 Sep 27; 24(6):1653-63. PubMed ID: 17004929
    [Abstract] [Full Text] [Related]

  • 20. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ.
    Am J Ther; 2007 Sep 27; 14(1):49-62. PubMed ID: 17303976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.